Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04093986 · ClinicalTrials.gov registry record

Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation

A clinical trial of Sickle Cell Disease and Sickle Cell Anemia, sponsored by Children's Hospital Medical Center, Cincinnati.

Recruiting
Registry status
200
Enrollment target
1
Study location

NCT04093986 is a study of Sickle Cell Disease and Sickle Cell Anemia that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 200 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (32% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04093986, a study of Sickle Cell Disease and Sickle Cell Anemia, is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.

RECRUITING
Registry status
200 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to document and understand the effects of hydroxyurea exposure for women with SCD and their babies, during both gestation and lactation.

Interventions

  • OTHER Survey
  • OTHER Chart Review

Study Locations (1)

Ohio

  • Cincinnati Children's Hospital Medical Center - Cincinnati

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2019-12-22
Est. Completion 2026-12

What the Registry Record Tells You About NCT04093986

The ClinicalTrials.gov registry entry for NCT04093986 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (32% lower). The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which Survey is the first listed.

NCT04093986 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT04093986 about?

NCT04093986 is a clinical study titled "Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation". The purpose of this research study is to document and understand the effects of hydroxyurea exposure for women with SCD and their babies, during both gestation and lactation.

What is the current status of trial NCT04093986?

This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2019-12-22. Estimated completion is 2026-12.

What conditions does trial NCT04093986 study?

This clinical trial studies the following conditions: Sickle Cell Disease, Sickle Cell Anemia.

What interventions are being tested in trial NCT04093986?

The interventions under investigation include: Survey (OTHER), Chart Review (OTHER).

Who is sponsoring clinical trial NCT04093986?

This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04093986 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.